NetworkNewsBreaks – Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) ‘Buy’ Rating, $25 PT Reiterated at Aegis Capital
Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) following the company’s recent report of financial results for the year ended December 31, 2016. Revenue was $174,000 for the year ended December 31, 2016, compared to $66.7 million for the year ended December 31, 2015. However, because Concert is a clinical-stage company, Aegis cited the events surrounding clinical trials rather than financials. In its earnings release, Concert also announced an asset acquisition agreement in which Vertex Pharmaceuticals will acquire Concert’s CTP-656 for up to $250 million. Concert expects…







